Scientists decode myeloma DNA to personalize future treatments

NCT ID NCT06338150

Recruiting now Knowledge-focused Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will analyze the genetic makeup of tumors from 100 people with relapsed multiple myeloma. Researchers will use advanced DNA and RNA sequencing to find genetic changes and understand how the cancer works. The goal is to gather information that could guide more personalized treatment choices in the future. Participants will provide blood, cheek swab, and tumor samples during routine care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better understand the genetic makeup of multiple myeloma and point toward more personalized treatment options.
What could go wrong: This is an early-stage observational study, not a treatment trial. It is not designed to test whether any specific therapy works, so results may not directly benefit participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Mount Sinai Health System
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.